Rifamycin

CAS Number6998-60-3
Molecular FormulaC37H47NO12
Molecular Weight697.8
InChI KeyHJYYPODYNSCCOU-ODRIEIDWSA-N
LogP4.9
Synonyms
  • RIFAMYCIN
  • Rifamycin SV
  • Rifamicine SV
  • Rifomycin SV
  • Rifamicina
  • Rifamycine
  • Rifamycinum
  • Rifocyn
  • 6998-60-3
  • RIFOMYCIN
  • DU69T8ZZPA
  • DTXSID1032014
  • CHEBI:29673
  • Rifamycin SV, an antibiotic produced by certain strains of Streptomyces mediterranei, or the same substance produced by any other means
  • [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
  • Rifamycine Chibret
  • 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione 21-acetate
  • ((7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo(23.3.1.14,7.05,28)triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl) acetate
  • (7S,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo(23.3.1.1^(4,7).0^(5,28))triaconta-1,3,5(28),9,19,21,25(29),26-octaen-13-yl acetate
  • (7S,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1,3,5(28),9,19,21,25(29),26-octaen-13-yl acetate
  • RefChem:57064
  • GlyTouCan:G97409XF
  • 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2-H)-dione, 21-acetate
  • DTXCID9012014
  • CHEBI:26580
  • A07AA13
  • D06AX15
  • J04AB03
  • S02AA12
  • G97409XF
  • 230-273-3
  • Rifamycins
  • Rifomycins
  • Rifocin
  • Aemcolo
  • M-14
  • 15105-92-7
  • 6998-60-3 (free acid)
  • NSC133100
  • Rifamycine [INN-French]
  • Rifamycinum [INN-Latin]
  • Tuborin
  • Rifamicina [INN-Spanish]
  • (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate
  • (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-Pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(28),2,4,9,19,21,25(29),26-octaen-13-yl acetate
  • EINECS 230-273-3
  • UNII-DU69T8ZZPA
  • rifamycin-sv
  • Rifamycin [USAN:INN:BAN:DCF]
  • RIFAMYCIN [INN]
  • Rifamycin (USAN/INN)
  • RIFAMYCIN [USAN]
  • RIFAMYCIN SV [MI]
  • RIFAMYCIN [WHO-DD]
  • SCHEMBL151824
  • CHEMBL437765
  • GTPL4570
  • SCHEMBL29355202
  • SCHEMBL29649054
  • HY-B1907A
  • 29),26-octaen-13-yl acetate
  • GLXC-20256
  • RIFAMYCIN SV [EP IMPURITY]
  • BDBM50391000
  • LMPK05000005
  • AKOS024281286
  • DB11753
  • 2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-, 21-acetate
  • ST044225
  • RIFAXIMIN IMPURITY C [EP IMPURITY]
  • CS-0092130
  • First International Standard for Rifamycin SV
  • D02549
  • SR-01000872597
  • SR-01000872597-1
  • (pentahydroxy-methoxy-heptamethyl-dioxo-[?]yl) acetate
  • Q26270990
  • (7S,11S,13S,17S,18S,12R,14R,15R,16R)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7 ,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1<4, 7>.0<5,28>]triaconta-1(28),2,4,9,19,21,25(
  • (7S,11S,13S,17S,18S,12R,14R,15R,16R)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7 ,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1<4, 7>.0<5,28>]triaconta-1(28),2,4,9,19,21,25(29),26-octaen-13-yl acetate
  • 2,7-(Epoxy[1,11,13]pentadecatrienoimino)naphtho[2,1-b]furan-1,11(2H)-dione, 21-(acetyloxy)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-, (2S,16S,17S,18R,19R,20R,21S,22R,23S)-

Applications:

Uv-Vis Spectrum of Rifamycin

March 9, 2026

Access the UV-Vis Spectrum SIELC Library

If you are looking for optimized HPLC method to analyze Rifamycin check our HPLC Applications library

For optimal results in HPLC analysis, it is recommended to measure absorbance at a wavelength that matches the absorption maximum of the compound(s) being analyzed. The UV spectrum shown can assist in selecting an appropriate wavelength for your analysis. Please note that certain mobile phases and buffers may block wavelengths below 230 nm, rendering absorbance measurement at these wavelengths ineffective. If detection below 230 nm is required, it is recommended to use acetonitrile and water as low UV-transparent mobile phases, with phosphoric acid and its salts, sulfuric acid, and TFA as buffers.
For some compounds, the UV-Vis Spectrum is affected by the pH of the mobile phase. The compound was diluted in acetonitrile.

Application Analytes:
Rifamycin
SIELC Technologies usually develops more than one method for each compound. Therefore, this particular method may not be the best available method from our portfolio for your specific application. Before you decide to implement this method in your research, please send us an email to research@sielc.com so we can ensure you get optimal results for your compound/s of interest.